GLYCOSYLATION AT ASN-184 INHIBITS THE CONVERSION OF SINGLE-CHAIN TO 2-CHAIN TISSUE-TYPE PLASMINOGEN-ACTIVATOR BY PLASMIN

被引:53
作者
WITTWER, AJ
HOWARD, SC
机构
[1] Department of Cell Culture and Biochemistry, Central Research Laboratories, Monsanto Company, St. Louis, Missouri 63167
关键词
D O I
10.1021/bi00469a021
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tissue-type plasminogen activator (tPA) is a glycosylated serine protease which is an effective thrombolytic agent. Native single-chain tPA (sc-tPA) is converted to two-chain tPA (tc-tPA) by plasmin, the product of the reaction of plasminogen with tPA. Native sc-tPA occurs as two glycoforms. Type I sc-tPA is fully glycosylated, while type II lacks glycosylation at Asn-184. The rates at which type I and type II human melanoma sc-tPA were converted to type I and type II tc-tPA by plasmin were determined by two different methods. In each case, the second-order rate constant (kcat/Km) for type II sc-tPA (~8 µM‒1 s‒1) was about twice that for type I sc-tPA (~4 µM‒1 s‒1). These results indicate that glycosylation at Asn-184 hinders the conversion of sc-tPA to tc-tPA and suggest that under physiological conditions type I sc-tPA may persist in the single-chain form longer than type II sc-tPA. Previous studies have shown that type I tc-tPA has a lower activity than type II tc-tPA and that sc-tPA has a lower activity and susceptibility to inhibition when compared to tc-tPA. The present work provides further evidence that tPA glycosylation serves to modulate activity. The two major glycoforms may represent more persistant but slow acting (type I) and less persistent but faster acting (type II) variants of tPA. © 1990, American Chemical Society. All rights reserved.
引用
收藏
页码:4175 / 4180
页数:6
相关论文
共 46 条
  • [1] TISSUE PLASMINOGEN-ACTIVATOR - CHEMICAL AND PHYSIOLOGICAL-ASPECTS
    BACHMANN, F
    KRUITHOF, IEKO
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1984, 10 (01) : 6 - 17
  • [2] THE SINGLE-CHAIN FORM OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR HAS CATALYTIC ACTIVITY - STUDIES WITH A MUTANT ENZYME THAT LACKS THE CLEAVAGE SITE
    BOOSE, JA
    KUISMANEN, E
    GERARD, R
    SAMBROOK, J
    GETHING, MJ
    [J]. BIOCHEMISTRY, 1989, 28 (02) : 635 - 643
  • [3] THROMBOLYTIC REPERFUSION OF ACUTE MYOCARDIAL-INFARCTION - RESOLVED AND UNRESOLVED ISSUES
    BRAUNWALD, E
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1988, 12 (06) : A85 - A92
  • [4] RECENT ADVANCES IN THE CHEMISTRY OF THE FIBRINOLYTIC SYSTEM
    CASTELLINO, FJ
    [J]. CHEMICAL REVIEWS, 1981, 81 (05) : 431 - 446
  • [5] KINETICS OF THE INHIBITION OF PLASMINOGEN ACTIVATORS BY THE PLASMINOGEN-ACTIVATOR INHIBITOR - EVIDENCE FOR 2ND SITE INTERACTIONS
    CHMIELEWSKA, J
    RANBY, M
    WIMAN, B
    [J]. BIOCHEMICAL JOURNAL, 1988, 251 (02) : 327 - 332
  • [6] CLELAND WW, 1967, ADV ENZYMOL RAMB, V29, P1
  • [7] CORONARY THROMBOLYSIS WITH RECOMBINANT HUMAN TISSUE-TYPE PLASMINOGEN-ACTIVATOR - A PROSPECTIVE, RANDOMIZED, PLACEBO-CONTROLLED TRIAL
    COLLEN, D
    TOPOL, EJ
    TIEFENBRUNN, AJ
    GOLD, HK
    WEISFELDT, ML
    SOBEL, BE
    LEINBACH, RC
    BRINKER, JA
    LUDBROOK, PA
    YASUDA, I
    BULKLEY, BH
    ROBISON, AK
    HUTTER, AM
    BELL, WR
    SPADARO, JJ
    KHAW, BA
    GROSSBARD, EB
    [J]. CIRCULATION, 1984, 70 (06) : 1012 - 1017
  • [8] COLLEN D, 1986, J BIOL CHEM, V261, P1259
  • [9] COLLEN D, 1988, THROMB RES, P3
  • [10] LARGE-SCALE PURIFICATION OF HUMAN TISSUE-TYPE PLASMINOGEN-ACTIVATOR USING MONOCLONAL-ANTIBODIES
    EINARSSON, M
    BRANDT, J
    KAPLAN, L
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1985, 830 (01) : 1 - 10